source
- Novartis investors grow wary as drug setbacks spark scrutiny of M&A strategyInvestors in Novartis are intensifying their examination of the company’s recent dealmaking after a series of setbacks involving drugs that were brought in through mergers and acquisitions. The hei…
- FDA leadership stabilizes under new CBER and CDER heads and appoints first AI deputy commissionerAt the Food and Drug Administration, Karim Mikhail and Michael Davis have been confirmed as the permanent heads of the Center for Biologics Evaluation and Research and the Center for Drug Evaluatio…